2008-11-10
Interim Report - January to September 2008
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused
on molecular imaging and targeted cancer treatments, today issued its Interim Report covering the
nine-month period ended September 30, 2008.
2008-09-05
Interim Report - January to June 2008
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on molecular imaging and targeted cancer treatments, today issued its Interim Report covering the First Half of 2008.
2008-05-08
Interim Report - January to March 2008
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused
on molecular imaging and targeted cancer treatments, today issued its Interim Report covering the
First Quarter 2008.
2008-02-07
Year-End Report 2007 in summary
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on molecular imaging and targeted cancer treatments, today issued its report for the full year 2007 in summary
2007-10-30
Interim Report – January to September 2007
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on molecular imaging and targeted cancer treatments, today issued its Interim Report covering the nine-month period ending September 30, 2007.
2007-08-29
Interim Report - January to June 2007
Affibody Holding AB (“Affibody” or “the Company”), a Swedish biotech company focused on molecular imaging and targeted cancer treatments today issued its Interim Report covering the six month period ending June 30, 2007.
2007-07-04
Affibody appoints Erik Walldén as CEO
STOCKHOLM, Sweden, July 4, 2007. The Swedish biotech company Affibody AB has appointed Erik Walldén as CEO and has elected two new members of the Board of Directors, Peter Buhl Jensen, MD, PhD and Gillies O’Bryan-Tear, MD. This represents a significant reinforcement of Affibody´s management competence.
2007-04-20
Håkan Åström appointed as new chairman of the board of Affibody
Affibody Holding AB, a biotech company that has developed a late-stage pipeline of oncology products for molecular imaging and targeted therapy, announces that the Annual General Meeting on 20 April 2007 appointed Håkan Åström as new chairman of the board and Ursula Ney as a new board member.
2007-03-30
Affibody issues new shares of SEK 200 million
Affibody Holding AB, a biotech company that has developed a late-stage pipeline of oncology products for molecular imaging and targeted therapy, issues new shares
amounting to SEK 200 million. Affibody’s mission is to provide the medical community with previously not available information for timely cancer diagnosis and appropriate
individualized treatment regimes.
2007-03-01
Affibody® molecules for cancer imaging made by chemical synthesis
STOCKHOLM, Sweden, March 1, 2007 - Affibody AB today announced that Cancer Research, the official publication of American Association of Cancer Research (AACR), has published an article demonstrating excellent visualization of HER2-expressing tumors using a chemically produced Affibody® molecule.
2006-08-16
Algeta and Affibody Initiate Anticancer Targeted Therapy Collaboration
OSLO, Norway, and STOCKHOLM, Sweden, August 16, 2006 - Algeta ASA, a therapeutics company developing novel anticancer agents based on alpha-particle emitting radionuclides, and Affibody AB, which is building a pipeline of products based on tumor-targeting affinity molecules, today announced a research collaboration agreement to develop novel targeted radiotherapeutics.
2006-06-19
Affibody AB and GE Healthcare Enter A Research Agreement
STOCKHOLM, Sweden, June 19, 2006 - Affibody AB today announced that the Company has entered a research agreement with GE Healthcare, a division of the General Electric Company. Under the agreement, Affibody will provide Affibody® molecules for three disease targets as defined by GE Healthcare.
2005-10-04
Affibody signs distribution agreement with Funakoshi
STOCKHOLM, Sweden and TOKYO, Japan, October 4, 2005 - Affibody AB and Funakoshi Co., Ltd., today announced an agreement in which Funakoshi will promote and distribute Affibody® biotechnology products in Japan.
2005-02-15
VINNOVA stödjer Affibody-forskning
VINNOVA stödjer forskning med syfte att utveckla Affibody-molekyler för medicinsk bildanalys och behandling av cancer. Totalt 5 miljoner kronor har tilldelats Affibody AB för samarbetsprojektet med KTH och Uppsala Universitet.
2005-02-02
Affibody starts sales of Affibody® molecules
Today, Affibody AB announces the launch of catalogue sales of its Affibody® molecules. These reagent products are designed for proteomics and bioseparation applications such as biomarker discovery, research diagnostics or separation of proteins, and present a cost-effective and well validated alternative to research use of antibodies.
2005-01-12
Affibody ingår treårigt leveransavtal
Affibody har ingått ett leveransavtal under vilket företaget kommer att leverera Affibody®-molekyler till Agilent under tre års tid. Molekylerna ska användas för att ta bort rikligt förekommande blodproteiner som försvårar diagnostiska undersökningar av proteiner som förekommer i blodet i lägre nivåer.